

## Ocaliva (obeticholic acid) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

**Instructions:** Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

			URGENT	
MEMBER INFORMATION				
LAST NAME:		FIRST NAME:		
PHONE NUMBER:		DATE OF BIRTH:		
STREET ADDRESS:				
CITY:		STATE: ZIP CODE:		
PATIENT INSURANCE ID NUN	/IBER:			
F YOU ARE NOT THE PATIENT OR THE PRESCRI FOLLOWING LINK: <u>HTTPS://MAGELLANRX.COM</u>	SHT (IN/CM): WEIGH BER, YOU WILL NEED TO SUBMIT A PHI DISCLO	ISURE AUTHORIZATION FORM WITH THIS REQU DN/DOC/EN-US/PHI DISCLOSURE AUTHORIZA	JEST WHICH CAN BE FOUND AT THE LTION.PDF	
PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE):				
PRESCRIBER INFORMATION				
LAST NAME:		FIRST NAME:		
PRESCRIBER SPECIALTY:		EMAIL ADDRESS:		
NPI NUMBER:		DEA NUMBER:		
PHONE NUMBER:		FAX NUMBER:		
STREET ADDRESS:				
CITY:		STATE: ZIP CODE:		
REQUESTOR (if different than prescriber):		OFFICE CONTACT PERSON:		
MEDICATION OR MEDICAL I	DISPENSING INFORMATION			
MEDICATION NAME:				
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:	
■ NEW THERAPY	RENEWAL	IF RENEWAL: DATE THERAPY	INITIATED:	
DURATION OF THERAPY (SPE	CIFIC DATES):			

Continued on next page.





## Ocaliva (obeticholic acid) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:		
1. HAS THE PATIENT TRIED ANY OTHI	ER MEDICATIONS FOR THIS CONDITION	YES (if yes, complete below) NO	
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:	
2. LIST DIAGNOSES:		ICD-10:	
☐ Primary biliary cholangitis (PBC, former☐ Other diagnosis:	ICD-10:		
PRIOR AUTHORIZATION.	N: PLEASE PROVIDE ALL RELEVANT CLINI	CAL INFORMATION TO SUPPORT A	
Clinical Information:	and the state of t		
	onsultation with a hepatologist or gastr	-	
Has the patient had an inadequate re	esponse to ursodeoxycholic acid (UDCA)	for at least one year? ☐ Yes ☐ No	
Will the patient be taking Ocaliva cor	ncurrently with ursodeoxycholic acid (U	DCA)? □ Yes □ No	
Has the patient tried and was unable	to tolerate ursodeoxycholic acid (UDCA	\)? □ Yes □ No	
improvement with both of the follow  ☐ Serum alkaline phosphatase (ALP)  ☐ Total bilirubin level of less than 1.1	positive clinical response to treatment ving:*	/dL for males	
Is Ocaliva being prescribed by or in co	onsultation with a hepatologist or gastr	oenterologist?   Yes   No	
Are there any other comments, diagonal physician feels is important to this re		ailed, and/or any other information the	
Please note: Not all drugs/diagnosis a information is received.	are covered on all plans. This request ma	y be denied unless all required	
	on provided is true and accurate to the b	est of my knowledge. I understand that	
	up or its designees may perform a routin	•	
information necessary to verify the ac	ccuracy of the information reported on the	nis form.	
Prescriber Signature or Electronic I.D		Date:	
you are not the intended recipient, you are he	companying this transmission contain confidential reby notified that any disclosure, copying, distribute undersized this information in error, please in the process of the company of the	ution, or action taken in reliance on the contents	

**FAX THIS FORM TO: 800-424-7640** 

MAIL REQUESTS TO: Magellan Rx Management, LLC

Attn: CP – 4201 P.O. Box 64811 St. Paul, MN 55164-0811





and arrange for the return or destruction of these documents.